Abstract
Sixteen patients suffering from widespread malignant disease, the majority pretreated and found in poor general health, were treated in a phase I pilot study with the alkyl lysophospholipid derivative 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (E-18-OCH3). Eleven patients were treated intravenously, and five were given oral therapy. Prolonged IV administration of 15–20 mg/kg/day at a concentration of 5 mg ET-18-OCH3 per 1 ml 20% human serum albumin could be continued safely. The maximum-tolerated dose was either 50 mg/kg as a single injection or 20 mg/kg during daily dispensions. Grade 2–4 toxicity, as pulmonary edema and impairment of hepatic function, then occurred during daily treatment. Toxicity was reversible. Mitogen stimulation and mixed lymphocyte culture studies revealed possible immunosuppressive effects of higher doses of ET-18-OCH3. There were no chromosomal changes in cytogenetic studies. Frequent post-mortem examinations revealed no further toxicity. IV and oral treatment showed few encouraging response data since there were two partial remissions in non-small cell lung cancers and a reduction of leukemic blasts to less than 10% in an acute myelomonocytic leukemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Berdel, W.E., Andreesen, R., and Munder, P.G. (1985) inPhospholipids and Cellular Regulation (Kuo, J.F., ed.) Vol. 2, pp. 41–73, CRC Press, Boca Raton, FL.
Berdel, W.E., Bausert, W.R.E., Fink, U., Rastetter, J., and Munder, P.G. (1981)Anticancer Res., 1, 345–352.
Berdel, W.E., Schlehe, H., Fink, U., Emmerich, B., Maubach, P.A., Emslander, H.P., Daum, S., and Rastetter, J. (1982)Cancer Philadelphia 50, 2011–2015.
Eibl, H.J., Arnold, D., Weltzien, H.U., and Westphal, O. (1967)Liebigs Ann. Chem. 709, 226–230.
Arnold, D., Weltzien, H.U., and Wesphal, O. (1967)Liebigs Ann. Chem. 709, 234–239.
Weltzien, H.U., and Westphal, O. (1967)Liebigs Ann. Chem. 709, 240–243.
Andreesen, R., Modolell, M., Weltzien, H.U., and Munder, P.G. (1979)Immunobiology 156, 498–508.
Bauchinger, M., Dresp, J., Schmid, E., and Berdel, W.E. (1983)Mutation Res. 121, 225–231.
Berdel, W.E., Fink, U., Schick, H.D., Weiss, G., and Rastetter, J. (1985) inEntwicklung, Prüfung und Anwendung von biologisch aktiven Substanzen in der Krebstherapie (Schuff-Werner, P., and Pfitzenmaier, K., eds.), pp. 215–230, W. Zuckschwerdt-Verlag, München.
Lee, T., and Snyder, F. (1985) inPhospholipids and Cellular Regulation (Kuo, J.F., ed.), Vol. II, pp. 1–39, CRC Press, Boca Raton, FL.
Author information
Authors and Affiliations
About this article
Cite this article
Berdel, W.E., Fink, U. & Rastetter, J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3 1 . Lipids 22, 967–969 (1987). https://doi.org/10.1007/BF02535566
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535566